Combined androgen blockade: An optimal therapy for minimally advanced prostate cancer?

British Journal of Urology

Volumn 81, Issue 1, 1998, Pages 87-95

  Soloway, M S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; NILUTAMIDE;

ADVANCED CANCER; DRUG EFFICACY; HORMONE INHIBITION; HUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0031847593     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00502.x     Document Type: Review

References (55)

1. Anon. National Cancer Institute. Cancer Facts, 1995
2. Muller Jensen 0, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. EurCancer 1990; 26: 1167-256
3. Trachtenberg J. Appraisal of current therapies for prostate cancer. Eur Urol 1996; 29 (Suppl. 2): 110-3
4. Gilliland F. Becker TM, Smith A et al. Trends in prostate cancer incidence and mortality in New Mexico are consistent with an increase in effective screening. Cancer Epidemiol. Biomarkers Prevention 1994; 3: 105-11
5. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54
6. Huggins C. Hodges CV. Studies in prostatic cancer. 1. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
7. Huggins C, Stevens RE, Hodges CV. Studies in prostatic cancer. II. The effects of castration on advanced cancer of the prostate gland. Arch Surg 1941: 43: 209-23
8. Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Cynecol Obstet 1967: 124: 1011-7
9. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. BrUrol 1997: 79: 235-46
10. Pilepich MV, Sause WT, Shipley WU et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology group. Urology 1995: 45: 616-23
11. Soloway MS. Shaifl R. Wajsman Z et al. Randomized prospective study comparing radical prostectomy alone versus radical prostectomy preceded by androgen blockade in clinical. B2 (T2bNxMO) prostate cancer. / Urol 1995: 154: 424-8
12. Fossa SD. Aass N. Opjodsmoen S. Assessment of quality of life in patients with prostate cancer. Semin Oncol 1994: 21: 657-61
13. 3 Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilboestrol in treatment of prostatic carcinoma. Urology Supplement 1989: 33: 45-52
14. Cassileth BR. Seidmon EJ, Soloway MS et al Patients' choice of the treatment in stage D prostate cancer. Urology 1989: 33: 57-62
15. Denis LJ. Whelan P. Carneiro de Moura JL et al Goserelin acetate and flutamide versus bilateral orchidectomy: a phase III EORTC trial (30853). Urology 1993: 42: 119-30
16. Crawford ED. Eisenberger MA. Mcleod DG et ni A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. Nnv Engl / Med 1989: 321: 419-24
17. 7 Janknegt RA. Abbou CC. Bartoletti R et al. Orchidectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. / Urol 1993: 149: 77-83
18. Crawford ED. Eisenberger MA. McLeod DG. Wilding G. Blumenstein BA. Comparison of bilateral orchiectomy with or without flutamide for the treatment of patients (PTS) with stage D2 adenocarcinoma of the prostate: results of NCI Intergroup Study 0105 (SWOG and ECOG). / Urol 1997: 157: 336 (Abs 1311)
19. Newling DWW. European trials and the management of prostate cancer. Sem Surg Oncol 1995: 11: 65-71
20. Crawford ED. Hussain M. DeAntoni EP et al Southwest Oncology Group strategies in prostatic carcinoma. Sem Surg Oncol 1995: 11: 60-4
21. Huggins C. Scott WW. Bilateral adrenalectomy in prostate cancer. Clinical features and urinary secretion of 17-ketosteroids and estrogen. Ann Surg 1945: 122: 1031-41
22. Geller J. Albert JD. DHT in prostate cancer tissue: a guide to management and therapy. Prostate 1985: 6: 19-25
23. 3 Robinson MRG. Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years. RrUrol 1980: 52: 328-9
24. McLeod DG. Kolvenbag GJCM. Defining the role of antiandrogens in the treatment of prostate cancer. Urology 1996: 47(Suppl. 1A): 85-9
25. Bracci U. DiSilverio F. Role of cyproterone acetate in urology. In Martini L. Motta M, eds. Androgens and Antiandrogens. New York: Raven Press. 1977: 3:53-9
26. Labrie F. Dupont A. Belanger A et al. New hormonal therapy in prostatic carcinoma. Combined treatment with an LH-RH agonist and an antiandrogen. Clin Invest Med 1982: 5: 267-75
27. Mahler C. Is disease flare a problem? Cancer 1993: 72: 3799-802
28. Janknegt RA, Maastricht NL. Crawford ED. Denver CO. Long-term efficacy and safety of maximal androgen blockade (MAB) with nilutamide (Anandron) and castration in stage D2 prostate cancer. Eur L'rol 1996: 30 (Suppl. 2): 264 (Abstr 991)
29. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995: 346: 265-9
30. Blumenstein BA. Some statistical considerations for the interpretation of trials of combined androgen therapy. Cancer 1993: 72: 3834-40
31. Suciu S. Sylvester R. Iversen P et al. Comparability of prostate cancer trials. Cancer 1993: 72: 3841-6
32. Keuppens F. Denis L. Smith P et al. Zoladex and flutamide versus bilateral orchidectomy. A randomized phase III EORTC 30853 study. Cancer 1990: 66: 1045-7
33. Klotz LH. Newman T. Total androgen blockade for metastatic prostate cancer: history and analysis of the PCTCG overview. CanUrol 1996: 3 (Suppl. 2): 102-5
34. Trachtenberg J. Progress in complete androgen blockade. Eur Urol 1997: 31 (Suppl. 2): 8-10
35. Scher HF. Kelly W. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. / Clin Oncol 1993: 11: 1566-72
36. Debruyne FM. de Gery A, Hucher M. Godfroid N. Maximum androgen blockade with nilutamide combined with orchidectomy in advanced prostate cancer: an updated metaanalysis of 7 randomised, placebo-controlled trials (1191 patients). Eur Urol 1996: 30 (Suppl. 2): 264(Abstr 990)
37. Bertagna C. DeGery A. Richer M. Francois JP. Zanirato J. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br }Urol 1994: 73: 396-402
38. Caubet J-F. Tosteson TD. Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a metaanalysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997: 49: 71-8
39. Eisenberger MA. Crawford ED, Wolf M ft al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT. 0036). Semin Oncol 1994: 21: 613-9
40. Crawford ED. Smith JA, Soloway MS et al. Treatment of stage D2 prostate cancer with leuprolide and Anandron compared to leuprolide and placebo. In Murphy G. Khoury S. Châtelain C. Denis L eds. Recent Advances in Urological Cancer Diagnosis and Treatment. Diagnostic and Therapeutic Progress in Urological Cancers. Paris: FUS. 1990: 61-2
41. Béland G. Elhilali M. Fradet Y et al. Total androgcn ablation: Canadian experience. Ural Clin North Am 1991: 18: 75-82
42. Debruyne FMJ. Dijkman GA. Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995; 28: 177-88
43. Brogden RN. Clissord SP. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 1989: 38: 185-203
44. Harris MG. Coleman SG. Faulds D. Chrisp P, Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostatic cancer. Drugs and Aging 1993; V. 9-25
45. Soloway MS. Schellhammer P. Sharifi R et al. A controlled trial of Casodex (bicalutamide) vs flutamide. each in combination with luteinizing hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Eur Urol 1996: 29 (Suppl. 2): 105-9
46. Schellhammer P. Sharifi R. Block NL et al. A controlled trial of bicalulamide versus flutamide. each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma: analysis of time to progression. Cancer 1996; 78: 2164-9
47. Schellhammer P, Shariti R. Block NL et al. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 1996; 47 Suppl. A): 54-60
48. Schellhammer P. Sharifi R. Block N et al. Clinical benefits of bicalutamide (Casodex) versus flutamide (Eulexin) in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind randomized, multicenter trial. Urologn 1997. in press
49. Schellhammer P. Soloway MS. Vogelzang NJ et al. Reply to letter by Zerbib M and Payan C. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 1996; 48: 661-3
50. Soloway M, Schellhammer P, Sharifi R et al. Analysis by extent of disease and race comparing Casodex with Eulexin, each combined with luteinizing hormone releasing hormone analogue therapy, in 813 patients with advanced prostate cancer. Presented at American Urological Association Annual Meeting 1996
51. Kaisary AV. Tyrrell CJ. Peeling WB. Griffiths K. Comparison of LH-RH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67: 502-8
52. The Leuprolide Study Group. Leuprolide versus diethylstilbesterol for metastatic prostate cancer. New EnglMed 1984; 311: 1281-6
53. Jorgensen T, Muller C, Kaalhus 0, Danielson HE, Tveter KJ. Extent of disease based on initial bone scan: important prognostic predictor for patients with metastatic prostatic cancer. Kitr Urol 1995: 28: 40-6
54. Labrie F. Dupont A. Cusan L, Gomez J-L, Diamond P. Major advantages of 'early' administration of endocrine combination therapy in advanced prostate cancer. Clin Invest Med 1993: 16: 493-8
55. Morote . Vallejo C. Lorente JA et al. Resultados detinitivos del bloqueo hormonal complete versus monotherapia en el cancer de prostata metastasico. Implications del PSA. Actas U ml Ksp 1995: 19: 604-10